Surgery Partners, Inc. (SGRY) Stock

Understand Surgery Partners, Inc.: how it makes money

Surgery Partners owns and operates 180 ambulatory surgery centers and surgical hospitals where physicians perform outpatient procedures, with the company earning a facility fee per case. Nearly all revenue comes from the surgical facility segment, supported by a thin ancillary layer (imaging, pharmacy, lab) at the same sites.

The company owns the operating room and charges a fixed facility fee per case while physicians retain the professional fee, so profit scales with case volume and the acuity (and reimbursement rate) of the procedures performed on those tables.

Business quality (Weak): Weak: revenue growing only at 3% YoY, operating margin at 12%, and ROE negative at minus 2%, reflecting a capital-intensive facility model under sustained payer pressure.

Bull case

• Acuity Mix Lifts Case Revenue: Management flagged that higher-acuity orthopedic and vascular procedures are driving revenue per case and overall growth, meaning the facility fee is rising on the back of case mix before volume effects even take hold.
• Physician Pipeline Re-Accelerating: New-recruit revenue came in up 16% versus last year's cohort, signaling that the internal investment in building out physician networks is producing incremental case flow at existing facilities.
• Inpatient-Only List Expands ASC Pool: Procedures leaving Medicare's inpatient-only list are now entering ASCs, which structurally widens the set of cases Surgery Partners can capture at its lower-cost ambulatory model versus traditional hospitals.

Bear case

• EBITDA Margin Compressing: Year-to-date EBITDA margin fell 80 basis points, pointing to cost or reimbursement pressure eroding the 12% operating margin and making the model less resilient to further payer pushback.
• Commercial Payer Mix Slipping: Commercial payer mix declined 350 basis points year over year, meaning a larger share of cases is shifting toward government payers with lower reimbursement rates, which puts direct downside pressure on revenue per case.
• Leverage Rises on Weaker Cash Flow: Quarter-end net debt sits at approximately 5.1 times EBITDA, a level that limits financial flexibility for the acquisition program that has historically fueled growth, especially as 2026 deal spend is expected to fall short of the prior $200 million annual target.

Related Companies (Healthcare Services; 8 comparable companies)

• Ardent Health Partners, LLC (ARDT)
• Community Health Systems, Inc. (CYH)
• Universal Health Services, Inc. (UHS)
• Tenet Healthcare Corporation (THC)
• Acadia Healthcare Company, Inc. (ACHC)
• AdaptHealth Corp. (AHCO)
• Brookdale Senior Living Inc. (BKD)
• Chemed Corporation (CHE)